Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2825-2832

  Van der Kaaij, Marleen A E ^a   Heutte, Natacha ^a   Le Stang, Nolwenn ^a   Raemaekers, John M M ^a   Simons, Arnold H M ^a   Carde, Patrice ^a   Noordijk, Evert M ^a   Fermé, Christophe ^a   Thomas, José ^a   Eghbali, Houchingue ^a   Kluin Nelemans, Hanneke C ^a   Henry Amar, Michel ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLLITROPIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FERTILITY; FOLLOW UP; GONAD FUNCTION; HEALTH CARE ORGANIZATION; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG EFFECT; MALE INFERTILITY; MULTICENTER STUDY; REGRESSION ANALYSIS; SPERMATOGENESIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; COHORT STUDIES; EUROPE; FOLLICLE STIMULATING HORMONE; HODGKIN DISEASE; HUMANS; INFERTILITY, MALE; MALE; REGRESSION ANALYSIS; SPERMATOGENESIS; TREATMENT OUTCOME;

EID: 34447576774     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2020     Document Type: Article

References (31)

1. Sieber M, Rueffer U, Josting A, et al: Treatment of Hodgkin's disease: Current strategies of the German Hodgkin's Lymphoma Study Group. Ann Oncol 10:23-29, 1999 (suppl 6)
2. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al: The achievements of the EORTC Lymphoma Group: European Organisation for Research and Treatment of Cancer. Eur J Cancer 38:S107-S113, 2002 (suppl 4)
3. Chen YT, Zheng T, Chou MC, et al: The increase of Hodgkin's disease incidence among young adults: Experience in Connecticut, 1935-1992. Cancer 79:2209-2218, 1997
4. Howell SJ, Shalet SM: Spermatogenesis after cancer treatment: Damage and recovery. J Natl Cancer Inst Monogr 12-17, 2005
5. Grigg A: The impact of conventional and high-dose therapy for lymphoma on fertility. Clin Lymphoma 5:84-88, 2004
6. Blumenfeld Z, Dann E, Avivi I, et al: Fertility after treatment for Hodgkin's disease. Ann Oncol 13:138-147, 2002 (suppl 1)
7. da Cunha MF, Meistrich ML, Fuller LM, et al: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571-577, 1984
8. Anselmo AP, Cartoni C, Bellantuono P, et al: Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP. Haematologica 75:155-158, 1990
9. Viviani S, Ragni G, Santoro A, et al: Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 27:1389-1392, 1991
10. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
11. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
12. DeVita VT Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
13. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
14. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139-143, 1982
15. Noordijk EM, Carde P, Dupouy N, et al: Combined modality therapy for all patients with clinical stage I-II Hodgkin's lymphoma. Long term results of the EORTC H7 randomized controlled trials (1988-1993). J Clin Oncol 24:3128-3135, 2006
16. Zittoun R, Eghbali H, Audebert A, et al: The combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP) before radiotherapy in localized stages of Hodgkin's disease. Phase II trials [French]. Bull Cancer 74:151-157, 1987
17. Klimo P, Connors JM: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182, 1985
18. Ferme C, Eghbali H, Meerwaldt JH, et al: Combined Modality Treatment for Early Stages Hodgkin's Lymphoma Based on Prognostic Factors. Results of the EORTC-GELA H8 Trial. N Engl J Med (in press)
19. Noordijk EM, Thomas J, Ferme C, et al: First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 23:561s, 2005 (suppl; abstr 6505)
20. Ferme C, Divine M, Vranovsky A, et al: Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-U trial. Proc Am Soc Hematol 106:813, 2005 (abstr)
21. Eghbali H, Brice P, Creemers GY, et al: Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Proc Am Soc Hematol 106:814, 2005 (abstr)
22. Diehl V, Sieber M, Ruffer U, et al: BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease: The German Hodgkin's Lymphoma Study Group. Ann Oncol 8:143-148, 1997
23. Rothman K, Boice J: Epidemiologic Analysis With a Programmable Calculator. Boston, MA, Epidemiology Resources Inc, 1982
24. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
25. Marmor D, Duyck F: Male reproductive potential after MOPP therapy for Hodgkin's disease: A long-term survey. Andrologia 27:99-106, 1995
26. Specht L, Geisler C, Hansen MM, et al: Testicular function in young men in long-term remission after treatment for the early stages of Hodgkin's disease. Scand J Haematol 33:356-362, 1984
27. Rowley MJ, Leach DR, Warner GA, et al: Effect of graded doses of ionizing radiation on the human testis. Radiat Res 59:665-678, 1974
28. Fraass BA, van de Geyn J: Peripheral dose from megavolt beams. Med Phys 10:809-818, 1983
29. Shapiro E, Kinsella TJ, Makuch RW, et al: Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol 3:1232-1239, 1985
30. Kinsella TJ, Trivette G, Rowland J, et al: Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin's disease. J Clin Oncol 7:718-724, 1989
31. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998